-
Xu, Z, Sharp, PP, Yao, Y, Segal, D, Ang, CH, Khaw, SL, Aubrey, BJ, Gong, J, Kelly, GL, Herold, MJ, et al.
BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.
Leukemia
30(7)
:
1531 -1541
2016
view publication
-
Ko, TK, San Chin, H, Chuah, CTH, Huang, JWJ, Ng, K-P, Khaw, SL, Huang, DCS, Ong, ST.
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
Oncotarget
7(3)
:
2721 -2733
2016
view publication
-
Khaw, SL, Mérino, D, Anderson, MA, Glaser, SP, Bouillet, P, Roberts, AW, Huang, DCS.
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
Leukemia
28(6)
:
1207 -1215
2014
view publication
-
Souers, AJ, Leverson, JD, Boghaert, ER, Ackler, SL, Catron, ND, Chen, J, Dayton, BD, Ding, H, Enschede, SH, Fairbrother, WJ, et al.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nature Medicine
19(2)
:
202 -208
2013
view publication
-
Mérino, D, Khaw, SL, Glaser, SP, Anderson, DJ, Belmont, LD, Wong, C, Yue, P, Robati, M, Phipson, B, Fairlie, WD, et al.
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Blood
119(24)
:
5807 -5816
2012
view publication